PATENTSCOPE will be unavailable a few hours for maintenance reason on Monday 03.02.2020 at 10:00 AM CET
Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1998052594) COMPOSITIONS FOR ENHANCING IMMUNOSUPPRESSANTS' PHARMACEUTICAL ACTIVITIES
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

O 98/52594
14
Claims

1. Any drug composition consisting of immunosuppressants cyclosporins, FK506, or rapamycin and the bioactive peptides related to the high-affinity binding/anti- lymphoproliferative site of interferons a,b,w,t or recombinant proteins carrying one or more of the sequences corresponding to the structures of the bioaςtive peptides related to the high-affinity binding anti-lymphoproliferative site of the said interferons for the aim of amplification of immunosuppressants' activities to decrease their therapeutic dose, and as the consequence to avoid their undesirable side effects during organ and tissue transplantation or during treatment of cancers such as lymphomas, leukemias, myelomas, adenocarcinomas, autoimmune and chronic inflammatory diseases, such as rheumatoid arthritis, myasthenia gravis, lupus erythematosis, uveitis, hyperproliferative diseases, such as psoriasis vulgaris, wherein cyclosporins, FK506 or rapamycin can be exploited.

2. Compositions according to Claim 1 consisting of immunosuppressants cyclosporins, FK506 or rapamycin with one or more of the peptides containing at least 5 identical amino acid residues in the following table:

wherein,

each amino acid residue in the top sequence can be modified with any of the amino acid residues under it.

3. Compositions according to Claim 1 consisting of immunosuppressants cyclosporins, FK506 or rapamycin, and recombinant proteins carrying one or more of the sequences corresponding to the peptide variation of Claim 2.

4. Compositions according to Claim 2 consisting of immunosuppressants cyclosporins, FK506 and rapamycin, and the bioactive peptides wherein the active peptides are genetically or chemically modified or genetically or chemically or physically bound to a small-molecular or macromolecular substance for the aim of increasing the stabilities of the peptides in physiological conditions or for regulating the bioavailability of the said peptides.